Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Hiroshi Aochi"'
Autor:
Mika Hosokawa, Keisuke Nagamine, Hiroshi Aochi, Kotarosumitomo Nakayama, Mikiko Sakuragi, Tamayo Morikawa, Mayumi Nakao, Tomoko Kiyokawa, Hisashi Kato, Yoshiaki Tomiyama, Hirokazu Kashiwagi
Publikováno v:
Japanese Journal of Transfusion and Cell Therapy. 68:412-421
Autor:
Mayumi Nakao, Hiroshi Aochi, Kotarosumitomo Nakayama, Mika Hosokawa, Mikiko Sakuragi, Tamayo Morikawa, Tomoko Kiyokawa, Keisuke Nagamine, Hisashi Kato, Hirokazu Kashiwagi, Yoshiaki Tomiyama
Publikováno v:
Japanese Journal of Transfusion and Cell Therapy. 68:28-33
Autor:
Hiroshi Aochi, Mika Hosokawa, Tomoko Kiyokawa, Mayumi Nakao, Tamayo Morikawa, Yoshiaki Tomiyama, Keisuke Nagamine, Kotarosumitomo Nakayama, Mikiko Sakuragi
Publikováno v:
Japanese Journal of Transfusion and Cell Therapy. 66:577-582
Autor:
Mikiko Sakuragi, Hiroshi Aochi, Hirohiko Shibayama, Yoshiaki Tomiyama, Kotarosumitomo Nakayama, Tomoko Kiyokawa, Mika Hosokawa, Mayumi Nakao, Hirokazu Kashiwagi, Keisuke Nagamine, Tamayo Morikawa
Publikováno v:
Japanese Journal of Transfusion and Cell Therapy. 65:600-605
Autor:
Tamayo Morikawa, Keisuke Nagamine, Mikiko Sakuragi, Hirohiko Shibayama, Hirokazu Kashiwagi, Hiroshi Aochi, Mika Hosokawa, Mayumi Nakao, Tomoko Kiyokawa, Yoshiaki Tomiyama, Kotarosumitomo Nakayama
Publikováno v:
Transfusion. 58:3003-3013
Background There is an increasing demand for daratumumab (DARA), an immunoglobulin (Ig)G1κ monoclonal antibody (MoAb) that recognizes CD38, to manage relapsed or refractory multiple myeloma (MM) patients. However, DARA leads to positive and panreact
Autor:
Mikiko Sakuragi, Yasuto Kinose, Tadashi Kimura, Tamayo Morikawa, Yongsook Koh, Tomoko Kiyokawa, Hiroyuki Ishii, Mika Hosokawa, Mayumi Nakao, Keisuke Nagamine, Yoshiaki Tomiyama, Kotarosumitomo Nakayama, Hiroshi Aochi, Tomoichiro Kuwazuru
Publikováno v:
Japanese Journal of Transfusion and Cell Therapy. 64:597-601
Autor:
Hisashi Kato, Mikiko Sakuragi, Tomoko Kiyokawa, Kotarousumitomo Nakayama, Yoshiaki Tomiyama, Hiroshi Aochi, Mika Hosokawa, Mayumi Nakao, Keisuke Nagamine, Tamayo Morikawa
Publikováno v:
Japanese Journal of Transfusion and Cell Therapy. 63:716-722
Autor:
Kotarosumitomo Nakayama, Mikiko Sakuragi, Hirohiko Shibayama, Hiroshi Aochi, Yoshiaki Tomiyama, Mika Hosokawa, Tamayo Morikawa, Mayumi Nakao, Hirokazu Kashiwagi, Keisuke Nagamine, Tomoko Kiyokawa
Publikováno v:
Transfusion. 59(7)
Autor:
Mika, Hosokawa, Hirokazu, Kashiwagi, Kotarosumitomo, Nakayama, Mikiko, Sakuragi, Mayumi, Nakao, Tamayo, Morikawa, Tomoko, Kiyokawa, Hiroshi, Aochi, Keisuke, Nagamine, Hirohiko, Shibayama, Yoshiaki, Tomiyama
Publikováno v:
Transfusion. 58(12)
There is an increasing demand for daratumumab (DARA), an immunoglobulin (Ig)G1κ monoclonal antibody (MoAb) that recognizes CD38, to manage relapsed or refractory multiple myeloma (MM) patients. However, DARA leads to positive and panreactive aggluti
Autor:
Yoshiaki Tomiyama, Hiroshi Aochi, Machiko Oshida, Keisuke Nagamine, Tamayo Ikeda, Mika Hosokawa, Mayumi Nakao, Tomoko Kiyokawa, Mikiko Sakuragi, Tomomi Kiyama
Publikováno v:
Japanese Journal of Transfusion and Cell Therapy. 59:579-585